StockData

Keros Therapeutics vs Stoke Therapeutics

KROS and STOK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KROS and STOK compare

Stoke Therapeutics is the larger company, worth 7.6 times as much as Keros Therapeutics ($1.7B against $224M).

Stoke Therapeutics grew revenue faster over the last twelve months (−86.2% versus −93.7% for Keros Therapeutics).

Keros Therapeutics keeps more of each dollar of sales as profit, with a net margin of −572% compared with −754% at Stoke Therapeutics.

Keros Therapeutics scores higher on the StockData Score (7 against 6 for Stoke Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKROSSTOK
Size and price
Market cap$224M$1.7B
Share price$11.31$26.41
Change, 1 year−34.5%−0.38%
Change, 5 years−79.8%5.2%
Beta (5Y)2.040.98
Employees78170
StockData Score
Total score7 (better)6
Valuation score1 (better)0
Growth score01 (better)
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/S15.4× (better)61.8×
P/B0.9× (better)4.9×
FCF yield−21.6%−10.6% (better)
Fair value–$9.66
Margin of safety–−173%
Growth
Revenue growth (TTM)−93.7%−86.2% (better)
Net income growth (TTM)−543%−496% (better)
EPS growth (TTM)−1287%−501% (better)
Profitability
Operating margin−698% (better)−810%
Net margin−572% (better)−754%
FCF margin−334% (better)−655%
Return on equity−17.2% (better)−61.1%
Return on invested capital−755%−252% (better)
Financial health
Debt / equity0.000.00
Interest coverage–−4856.0×
Current ratio21.96 (better)7.69
Altman Z-score2.6718.01 (better)
Piotroski F-score6 (better)5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions101%120%
Held by insiders53.3%41.6%
Insider net buying, 12 months−$453K (better)−$6.7M
Short interest, % of float11.7%28.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.